Pathophysiology of Romosozumab-Associated Cardiovascular Risk
The exact pathophysiological mechanism underlying romosozumab's cardiovascular risk remains incompletely understood, but the signal emerged from clinical trial data showing increased serious cardiovascular events compared to alendronate, despite no such signal versus placebo. 1
Clinical Evidence of Cardiovascular Risk
The cardiovascular safety concern stems specifically from the ARCH trial (N=4,093), where serious cardiovascular events were significantly more common with romosozumab compared to alendronate 1. Critically, this increased risk was small and did not persist beyond the treatment period. In contrast, the larger FRAME trial (N=7,180) comparing romosozumab to placebo showed no such cardiovascular signal 1.
This discrepancy between trials creates an important clinical paradox: why would romosozumab show increased cardiovascular events versus an active comparator but not versus placebo?
Proposed Mechanisms
Sclerostin's Role in Vascular Biology
Sclerostin is expressed not only in bone but also in aortic vascular smooth muscle (AVSM) 2. In vascular tissue, sclerostin has been proposed to:
- Inhibit vascular calcification
- Reduce atherosclerotic progression
- Modulate vascular inflammation
By inhibiting sclerostin, romosozumab theoretically could remove these protective vascular effects 2.
Nonclinical Studies Show No Direct Cardiovascular Toxicity
However, comprehensive nonclinical toxicology studies in animal models—including those with atherosclerosis—found no functional, morphological, or transcriptional cardiovascular effects despite pharmacodynamic bone effects 2. These studies revealed no evidence of:
- Adverse cardiovascular function
- Increased cardiovascular calcification
- Atherosclerotic progression
This disconnect between theoretical mechanism and animal data suggests the cardiovascular signal may not be a direct pharmacologic effect of sclerostin inhibition 2.
Potential Platelet Dynamics
Emerging case reports suggest romosozumab may affect platelet dynamics and hematopoietic stem cell function 3. One case documented platelet count normalization in a patient with immune thrombocytopenic purpura following romosozumab treatment, raising questions about off-target hematopoietic effects that could theoretically influence thrombotic risk 3.
The Dual Mechanism Hypothesis
Romosozumab has a dual action mechanism: it increases bone formation while simultaneously decreasing bone resorption 4. This differs from pure anabolic agents like teriparatide. The antiresorptive component could theoretically contribute to cardiovascular effects, though this remains speculative.
Real-World Evidence Provides Conflicting Data
Recent real-world studies show divergent findings:
In patients WITHOUT prior cardiovascular disease: Romosozumab was associated with LOWER risks of 3-point MACE at 3-year (HR 0.645) and 5-year follow-up (HR 0.755) compared to denosumab 5
In patients WITH prior cardiovascular disease: Romosozumab showed consistently HIGHER cardiovascular risks across all follow-up periods 5
Japanese nationwide database study: No excess cardiovascular events with romosozumab versus other anti-osteoporosis medications after adjustment 6
Korean multicenter study: No significant difference in MACE or cardiovascular adverse events between romosozumab and denosumab at 1- or 3-year follow-up 7
Clinical Implications for Your Patient
For a patient with severe osteoporosis and prior myocardial infarction, romosozumab carries a black-box warning and is contraindicated 1. The FDA label explicitly states romosozumab should not be initiated in patients with myocardial infarction or stroke in the preceding year 4.
Key Pathophysiologic Considerations:
The cardiovascular risk appears patient-specific rather than drug-universal: Real-world data suggest the risk concentrates in those with preexisting cardiovascular disease 5
The mechanism may involve patient-drug interaction: The ARCH trial comparison to alendronate (which may have cardioprotective effects) versus the neutral FRAME placebo comparison suggests the signal may reflect relative rather than absolute risk
Timing matters: The increased cardiovascular events in ARCH occurred during the 12-month treatment period and did not persist afterward 1
Bottom Line
The pathophysiology remains uncertain, but the clinical reality is that romosozumab should be avoided in patients with recent MI or stroke, and used cautiously in those with high cardiovascular risk 1. The mechanism likely involves complex interactions between sclerostin inhibition, preexisting vascular disease, and possibly platelet dynamics—but nonclinical studies have not identified a direct causal pathway 2.